Inflexion’s experience in our sector, steering acquisitions and the immense task of carve-outs made them incredibly well suited to our ambitions. They bring substantially more than pure capital to our plans.

Guy Clark CEO, CNX Therapeutics

About 

CNX Therapeutics was formed in 2021 when Inflexion carved out the European operations of US-based Sunovion Pharmaceuticals.  

CNX supplies essential medicines with a portfolio of speciality brands and hospital products. The carve out included the pan-European licensing rights to a patent-protected medicine used for the treatment of schizophrenia. 

Value acceleration  

Inflexion’s substantial experience in carve-outs and healthcare helped create CNX as an independent entity. Since then, it’s built up a product portfolio to develop a scaled European platform focused on hospital and central nervous system (“CNS”)  therapies. A year after carve-out, CNX acquired Synchrony Pharma and Inflexion’s digital team is supporting CNX to make the most of automation and data visualisation. In 2023 / 2024 the business acquired two central nervous products from Eisai to treat psychological disorders and Parkinson’s disease, as well as four hospital products from Clinigen and two central nervous products from Sanofi. 

Inflexion’s experience in our sector, steering acquisitions and the immense task of carve-outs made them incredibly well suited to our ambitions. They bring substantially more than pure capital to our plans.

Guy Clark CEO, CNX Therapeutics